targeted therapy can delay recurrence of intermediate-stage lung cancer
The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor ...
May 18, 2017